| scholarly article | Q13442814 |
| P2093 | author name string | Giovanni Targher | |
| Christopher Day | |||
| Lorenzo Bertolini | |||
| Luciano Zenari | |||
| Guido Arcaro | |||
| Roberto Padovani | |||
| Roberto Tessari | |||
| Stefano Rodella | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cardiovascular disease | Q389735 |
| liver disease | Q929737 | ||
| metabolic dysfunction–associated steatotic liver disease | Q1546498 | ||
| fatty liver disease | Q6058862 | ||
| P304 | page(s) | 1212-1218 | |
| P577 | publication date | 2007-02-02 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. | |
| P478 | volume | 30 |
| Q36298719 | "Non alcoholic fatty liver disease and eNOS dysfunction in humans" |
| Q44744077 | A history of previous gestational diabetes mellitus is associated with adverse changes in insulin secretion and VLDL metabolism independently of increased intrahepatocellular lipid |
| Q34301287 | A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease |
| Q46505404 | A modified Mediterranean diet is associated with the greatest reduction in alanine aminotransferase levels in obese type 2 diabetes patients: results of a quasi-randomised controlled trial |
| Q59075025 | A novel role of globular adiponectin in treatment with HFD/STZ induced T2DM combined with NAFLD rats |
| Q35910654 | A randomised controlled trial of a Mediterranean Dietary Intervention for Adults with Non Alcoholic Fatty Liver Disease (MEDINA): study protocol |
| Q92524269 | A randomized controlled trial on the effectiveness of 8-week high-intensity interval exercise on intrahepatic triglycerides, visceral lipids, and health-related quality of life in diabetic obese patients with nonalcoholic fatty liver disease |
| Q40248747 | A study of gender-wise risk association between fatty liver and metabolic syndrome components (Asia-Pacific criteria) in a South Indian urban cohort |
| Q57494349 | A systematic review of the present and future of non-alcoholic fatty liver disease |
| Q35039525 | Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease |
| Q28074228 | Acute kidney injury and post-reperfusion syndrome in liver transplantation |
| Q26795529 | Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma |
| Q36329908 | Advances in the treatment of nonalcoholic fatty liver disease |
| Q40793528 | Adverse outcomes of pregnancy in women with non-alcoholic fatty liver disease |
| Q41630408 | Aerobic capacity and hepatic mitochondrial lipid oxidation alters susceptibility for chronic high-fat diet-induced hepatic steatosis. |
| Q53800431 | Age at menarche is associated with the prevalence of non-alcoholic fatty liver disease later in life. |
| Q33905587 | Alcoholic fatty liver disease elevates estimated coronary heart disease risk to levels comparable with those of nonalcoholic fatty liver disease in the Korean population: a cross-sectional study |
| Q42377453 | Aliskiren effect on non-alcoholic steatohepatitis in metabolic syndrome |
| Q34574104 | Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease |
| Q37385527 | Assessment of the relationship between non-alcoholic fatty liver disease and diabetic complications |
| Q36348736 | Association between Insulin Resistance, Metabolic Syndrome and Nonalcoholic Fatty Liver Disease in Chinese Adults |
| Q34976232 | Association between inflammatory markers and liver fat: The Multi-Ethnic Study of Atherosclerosis |
| Q37282849 | Association between nonalcoholic fatty liver disease and the incidence of cardiovascular and renal events |
| Q36584582 | Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988-1994 |
| Q92471129 | Association of Pro-inflammatory Dietary Intake and Non-Alcoholic Fatty Liver Disease: Findings from Iranian case-control study |
| Q94525942 | Association of Serum Fibroblast Growth Factor 23 Levels with the Presence and Severity of Hepatic Steatosis Is Independent of Sleep Duration in Patients with Diabetes |
| Q54312430 | Association of fatty liver disease with nonfatal cardiovascular events in patients undergoing maintenance hemodialysis. |
| Q38975657 | Association of grade of non-alcoholic fatty liver disease and glycated albumin to glycated hemoglobin ratio in patients with type 2 diabetes mellitus. |
| Q36134867 | Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis |
| Q38464557 | Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women |
| Q43489996 | Awareness and opinions of non-alcoholic fatty liver disease by hospital specialists |
| Q97524395 | Beneficial effects of Chinese herbs in the treatment of fatty liver diseases |
| Q43144562 | Berry meals and risk factors associated with metabolic syndrome. |
| Q26765455 | Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome |
| Q91876988 | CHD is Associated With Higher Grades of NAFLD Predicted by Liver Stiffness |
| Q46248847 | Caffeoylquinic Acid-Rich Extract of Aster glehni F. Schmidt Ameliorates Nonalcoholic Fatty Liver through the Regulation of PPARδ and Adiponectin in ApoE KO Mice. |
| Q82622816 | Cardiometabolic comorbidities and the approach to patients with psoriasis |
| Q38711424 | Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease |
| Q38974667 | Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. |
| Q57191819 | Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders |
| Q38168505 | Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds. |
| Q35769495 | Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. |
| Q37596187 | Clinical approaches to non-alcoholic fatty liver disease |
| Q34005976 | Clinical correlation of nonalcoholic fatty liver disease in a Chinese taxi drivers population in Taiwan: Experience at a teaching hospital |
| Q37575417 | Combining metformin and aerobic exercise training in the treatment of type 2 diabetes and NAFLD in OLETF rats. |
| Q94525968 | Common and Unique Factors and the Bidirectional Relationship Between Chronic Kidney Disease and Nonalcoholic Fatty Liver in Type 2 Diabetes Patients |
| Q36952218 | Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. |
| Q49454549 | Correlation of blood glucose, serum chemerin and insulin resistance with NAFLD in patients with type 2 diabetes mellitus |
| Q30385602 | Cost-utility analysis of nonalcoholic steatohepatitis screening. |
| Q37859419 | Current therapeutic strategies in non-alcoholic fatty liver disease. |
| Q33645706 | Depression and Chronic Liver Diseases: Are There Shared Underlying Mechanisms? |
| Q36218142 | Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms. |
| Q51182919 | Development of non-invasive method for assessment of hepatic steatosis. |
| Q58761052 | Diabetes and Exposure to Environmental Lead (Pb) |
| Q40147836 | Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. |
| Q38261236 | Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. |
| Q38811383 | Diagnosis of non-alcoholic fatty liver disease (NAFLD). |
| Q30354434 | Differences between healthy adults and patients with type 2 diabetes mellitus in reactivity of toe microcirculation by ultrasound combined with a warm bath test |
| Q47692256 | Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes. |
| Q37400771 | Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene |
| Q49805564 | Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease? |
| Q26776043 | Does Lysosomial Acid Lipase Reduction Play a Role in Adult Non-Alcoholic Fatty Liver Disease? |
| Q37874856 | Does physical inactivity cause nonalcoholic fatty liver disease? |
| Q38016566 | Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. |
| Q37356739 | Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function |
| Q41836078 | Effect of Daisaikoto on Expressions of SIRT1 and NF-kappaB of Diabetic Fatty Liver Rats Induced by High-Fat Diet and Streptozotocin |
| Q58724925 | Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease |
| Q30496725 | Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes |
| Q51702668 | Effects of acute exercise on lipid content and dietary lipid uptake in liver and skeletal muscle of lean and diabetic rats. |
| Q42101166 | Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes |
| Q28071597 | Effects of exercise training on intrahepatic lipid content in humans |
| Q27025423 | Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes |
| Q93353103 | Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease |
| Q37616144 | Evaluation of Beneficial Metabolic Effects of Berries in High-Fat Fed C57BL/6J Mice. |
| Q36219719 | Evaluation of Effects of Chinese Prescription Kangen-karyu on Diabetes-Induced Alterations such as Oxidative Stress and Apoptosis in the Liver of Type 2 Diabetic db/db Mice |
| Q58734575 | Evaluation of a High Concentrate Omega-3 for Correcting the Omega-3 Fatty Acid Nutritional Deficiency in Non-Alcoholic Fatty Liver Disease (CONDIN) |
| Q36670931 | Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks |
| Q64080866 | Experimental non-alcoholic steatohepatitis in Göttingen Minipigs: consequences of high fat-fructose-cholesterol diet and diabetes |
| Q37237978 | Exploration of a symptoms experience in people with obesity-related nonalcoholic fatty liver disease. |
| Q40107676 | External validation of non-invasive prediction models for identifying ultrasonography-diagnosed fatty liver disease in a Chinese population |
| Q36921610 | Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease |
| Q92722364 | Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease |
| Q38134034 | Extrahepatic complications of nonalcoholic fatty liver disease |
| Q48225055 | Fatty allograft and cardiovascular outcomes after liver transplantation |
| Q34163162 | Fatty liver deposition and sparing: a pictorial review |
| Q43105416 | Fatty liver incidence and predictive variables |
| Q28079826 | Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV |
| Q40707205 | Fatty liver score and 15-year incidence of type 2 diabetes |
| Q38915869 | Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects |
| Q42972173 | Frequency and risk factors associated with non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus |
| Q57641851 | Frequency of incidental fatty liver on ultrasound and its association with diabetes mellitus and hypertension |
| Q38258947 | Galectin-3: an emerging all-out player in metabolic disorders and their complications |
| Q37583757 | Gamma-glutamyl transferase and cardiovascular disease |
| Q37150528 | Genes and nonalcoholic fatty liver disease |
| Q51395389 | Genetic variation in the GCKR gene is associated with non-alcoholic fatty liver disease in Chinese people. |
| Q38389889 | Ghrelin-ghrelin O-acyltransferase system in the pathogenesis of nonalcoholic fatty liver disease |
| Q45067817 | Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention |
| Q37483740 | Glucose abnormalities in non-alcoholic fatty liver disease and chronic hepatitis C virus infection: the role of iron overload. |
| Q35785648 | Gut Microbial Fatty Acid Metabolites Reduce Triacylglycerol Levels in Hepatocytes. |
| Q61808846 | Health and Economic Burden of Nonalcoholic Fatty Liver Disease in the United States and Its Impact on Veterans |
| Q35147488 | Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan. |
| Q35809069 | Hepatic Steatosis as a Marker of Metabolic Dysfunction. |
| Q64094413 | Hepatic miR‑215 target Rictor and modulation of hepatic insulin signalling in rats |
| Q53098351 | Hepatic steatosis in diabetic patients does not predict adverse liver-related or cardiovascular outcomes. |
| Q42997997 | Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors. |
| Q38009669 | Hepatic steatosis in type 1 diabetes |
| Q35140808 | Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation |
| Q35126823 | Hepatokines as a Link between Obesity and Cardiovascular Diseases |
| Q38467491 | High prevalence of cardiovascular disease in South Asians: Central role for brown adipose tissue? |
| Q46628692 | Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors |
| Q34306736 | Histopathology of nonalcoholic fatty liver disease |
| Q35250416 | IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis |
| Q61808847 | Identifying and Treating Nonalcoholic Fatty Liver Disease |
| Q28079713 | Immune Imbalances in Non-Alcoholic Fatty Liver Disease: From General Biomarkers and Neutrophils to Interleukin-17 Axis Activation and New Therapeutic Targets |
| Q35993416 | Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease |
| Q37906992 | Increased prevalence of cardiovascular disease in Type 1 diabetic patients with non-alcoholic fatty liver disease. |
| Q51384671 | Increased prevalence of non-alcoholic fatty liver disease in European women with a history of gestational diabetes. |
| Q40959440 | Increased risk for development of coronary artery calcification in subjects with non-alcoholic fatty liver disease and systemic inflammation |
| Q36796750 | Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease |
| Q38008136 | Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. |
| Q37258329 | Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? |
| Q46220517 | Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: A prospective study. |
| Q36896377 | Increasing whole grain intake as part of prevention and treatment of nonalcoholic Fatty liver disease. |
| Q34729697 | Independent Association between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: A Systematic Review and Meta-Analysis |
| Q30453231 | Inflammation in nonalcoholic steatohepatitis |
| Q33789340 | Inhibition of SREBP transcriptional activity by a boron-containing compound improves lipid homeostasis in diet-induced obesity |
| Q36693152 | Inhibition of apoptosis in the management of nonalcoholic fatty liver disease |
| Q64355676 | Insights into the Role of PPARβ/δ in NAFLD |
| Q48133244 | Integrative analysis of super enhancer SNPs for type 2 diabetes |
| Q49261126 | Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. |
| Q35592598 | Intravoxel Incoherent Motion Diffusion Weighted MR Imaging at 3.0 T: Assessment of Steatohepatitis and Fibrosis Compared with Liver Biopsy in Type 2 Diabetic Patients |
| Q34575945 | Is MR spectroscopy really the best MR-based method for the evaluation of fatty liver in diabetic patients in clinical practice? |
| Q94475601 | Is it time for non-alcoholic fatty liver disease screening in patients with type 2 diabetes mellitus? |
| Q34962813 | Is there any progress in the treatment of non-alcoholic fatty liver disease? |
| Q37351506 | Jiao tai wan attenuates hepatic lipid accumulation in type 2 diabetes mellitus |
| Q37488800 | KASL clinical practice guidelines: management of nonalcoholic fatty liver disease |
| Q61958591 | Kombiglyze (metformin and saxagliptin)-induced hepatotoxicity in a patient with non-alcoholic fatty liver disease |
| Q26829532 | Lessons from mouse models of high-fat diet-induced NAFLD |
| Q36131261 | Lifestyle intervention in non-alcoholic fatty liver disease in Chengyang District, Qingdao, China |
| Q41694135 | Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets |
| Q27024352 | Lipid-lowering agents in the management of nonalcoholic fatty liver disease |
| Q38603046 | Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma of type 2 diabetics with cardiovascular co-morbidities. |
| Q33751826 | Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage |
| Q33791133 | Liver fat: a relevant target for dietary intervention? Summary of a Unilever workshop |
| Q39758401 | Liver-related mortality in countries of the developed world: an ecological study approach to explain the variability. |
| Q57295709 | Longitudinal Comparison of the Effect of Gastric Bypass to Sleeve Gastrectomy on Liver Function in a Bariatric Cohort: Tehran Obesity Treatment Study (TOTS) |
| Q48215130 | Low prevalence of non-alcoholic fatty liver disease in patients with type 1 diabetes is associated with decreased subclinical cardiovascular disease |
| Q51330490 | Low serum sex hormone-binding globulin is associated with nonalcoholic fatty liver disease in type 2 diabetic patients. |
| Q91839872 | Low-Magnitude High-Frequency Vibration Decreases Body Weight Gain and Increases Muscle Strength by Enhancing the p38 and AMPK Pathways in db/db Mice |
| Q38625205 | MRI-determined liver proton density fat fraction, with MRS validation: Comparison of regions of interest sampling methods in patients with type 2 diabetes |
| Q38365276 | Management and diagnosis of fatty liver disease |
| Q53704720 | Managing the Burden of Non-NASH NAFLD. |
| Q51280945 | Maternal obesity programs offspring nonalcoholic fatty liver disease by innate immune dysfunction in mice. |
| Q43233646 | Mean platelet volume in patients with non-alcoholic fatty liver disease |
| Q35588261 | Mechanism of the effect of glycosyltransferase GLT8D2 on fatty liver |
| Q33570396 | Mediterranean diet and diabetes: prevention and treatment |
| Q51289305 | Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes. |
| Q92776030 | Metformin Attenuates Liver Fat Content: Finding from Schizophrenia Patients with Olanzapine-induced Weight Gain |
| Q64093621 | MiR-15b can target insulin receptor to regulate hepatic insulin signaling in mice |
| Q91695771 | Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study |
| Q90575879 | Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease |
| Q37505457 | Multicenter investigation of lifestyle-related diseases and visceral disorders in thalidomide embryopathy at around 50 years of age. |
| Q92856739 | NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment |
| Q90193044 | NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome |
| Q26750955 | NAFLD and Increased Aortic Stiffness: Parallel or Common Physiopathological Mechanisms? |
| Q90599751 | NAFLD and cardiovascular disease |
| Q38978347 | NAFLD and diabetes mellitus |
| Q80964439 | NASH predicts plasma inflammatory biomarkers independently of visceral fat in men |
| Q89687819 | Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach |
| Q37437435 | New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). |
| Q36063593 | No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. |
| Q33675914 | Non-Alcoholic Fatty Liver Disease Association with Cardiac Arrhythmias |
| Q53695403 | Non-Alcoholic Fatty Liver Disease and Associated Factors among Type 2 Diabetic Patients in Southwest Ethiopia. |
| Q46860543 | Non-Alcoholic Fatty Liver Disease in Africa and Middle East: An Attempt to Predict the Present and Future Implications on the Healthcare System |
| Q51287371 | Non-Alcoholic Fatty Liver Disease in Early Pregnancy Predicts Dysglycemia in Mid-Pregnancy: Prospective Study. |
| Q39030264 | Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome |
| Q35819344 | Non-alcohol fatty liver disease in Asia: Prevention and planning |
| Q37613517 | Non-alcoholic Fatty Liver Disease: East Versus West |
| Q37002532 | Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease |
| Q35668765 | Non-alcoholic fatty liver disease - the heart of the matter |
| Q38052857 | Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences |
| Q37091659 | Non-alcoholic fatty liver disease and diabetes |
| Q26852019 | Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment |
| Q57283707 | Non-alcoholic fatty liver disease and obesity: the role of the gut bacteria |
| Q64052598 | Non-alcoholic fatty liver disease and pregnancy complications among Sri Lankan women: A cross sectional analytical study |
| Q41150051 | Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis |
| Q41887942 | Non-alcoholic fatty liver disease in a patient with maturity onset diabetes in the young |
| Q58722876 | Non-alcoholic fatty liver disease is a strong predictor of coronary artery calcification in metabolically healthy subjects: A cross-sectional, population-based study in middle-aged subjects |
| Q94479096 | Non-alcoholic fatty liver disease is associated with cardiovascular disease in subjects with different glucose tolerance |
| Q33308506 | Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients |
| Q84006151 | Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients |
| Q36432536 | Non-alcoholic fatty liver disease is not related to the incidence of diabetic nephropathy in Type 2 Diabetes |
| Q35543956 | Non-alcoholic fatty liver disease: The diagnosis and management |
| Q37869883 | Non-alcoholic fatty liver disease: a massive problem. |
| Q27006131 | Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging |
| Q38128548 | Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification |
| Q37693238 | Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome |
| Q30414504 | Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease |
| Q30366569 | Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. |
| Q47793060 | Non-obese fatty liver disease is associated with lacunar infarct. |
| Q35740071 | Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes |
| Q88611062 | Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter |
| Q92982252 | Nonalcoholic Fatty Liver Diseases among Recently Diagnosed Patients with Diabetes Mellitus and Risk Factors |
| Q26827169 | Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians? |
| Q37375539 | Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment |
| Q89216668 | Nonalcoholic fatty liver disease |
| Q38592767 | Nonalcoholic fatty liver disease - current status and future directions |
| Q38052858 | Nonalcoholic fatty liver disease and atherosclerosis |
| Q36520139 | Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists? |
| Q37318761 | Nonalcoholic fatty liver disease and cardiovascular risk |
| Q49501260 | Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus |
| Q36872035 | Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes |
| Q37750546 | Nonalcoholic fatty liver disease and the coronary artery disease |
| Q38071416 | Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment |
| Q37278131 | Nonalcoholic fatty liver disease in a district general hospital: clinical presentation and risk factors |
| Q35088712 | Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus |
| Q35258097 | Nonalcoholic fatty liver disease is associated with coronary artery calcium score in diabetes patients with higher HbA1c |
| Q45852475 | Nonalcoholic fatty liver disease is associated with insulin resistance in a young Hispanic population |
| Q53063936 | Nonalcoholic fatty liver disease is associated with significant coronary artery disease in type 2 diabetic patients: a computed tomography angiography study 2：. |
| Q37119289 | Nonalcoholic fatty liver disease: diagnosis and relation to metabolic syndrome and approach to treatment |
| Q84988442 | Nonalcoholic steatohepatitis (NASH) does not increase complications after laparoscopic bariatric surgery |
| Q37286751 | Nutritional management of insulin resistance in nonalcoholic fatty liver disease (NAFLD). |
| Q37337328 | Obesity and the extent of liver damage among adult New Zealanders: findings from a national survey |
| Q37774235 | Obesity-related non-communicable diseases: South Asians vs White Caucasians |
| Q24612841 | Obstructive sleep apnea syndrome and fatty liver: Association or causal link? |
| Q90319834 | Overview of studies of the vitamin D/vitamin D receptor system in the development of non-alcoholic fatty liver disease |
| Q39151146 | Oxidized eicosapentaenoic acids more potently reduce LXRα-induced cellular triacylglycerol via suppression of SREBP-1c, PGC-1β and GPA than its intact form. |
| Q34998991 | PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease |
| Q51439742 | PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes. |
| Q33606303 | Pathogenesis of non-alcoholic fatty liver disease. |
| Q34813427 | Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause |
| Q83094715 | Pathology of nonalcoholic fatty liver disease |
| Q51338670 | Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. |
| Q35171570 | Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk |
| Q57478506 | Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus |
| Q92372255 | Perspectives on Interval Exercise Interventions for Non-Alcoholic Fatty Liver Disease |
| Q37910902 | Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. |
| Q33937311 | Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes. |
| Q46569190 | Predictive value of dobutamine stress echocardiography for coronary artery disease detection in liver transplant candidates |
| Q38985095 | Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. |
| Q90137657 | Prevalence and Association of Elevated Liver Transaminases in Type 2 Diabetes Mellitus Patients in Jeddah, Saudi Arabia |
| Q37118863 | Prevalence and features of fatty liver detected by physical examination in Guangzhou |
| Q47228561 | Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital. |
| Q35043760 | Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study |
| Q33947985 | Prevalence of metabolic syndrome and risks of abnormal serum alanine aminotransferase in Hispanics: a population-based study. |
| Q42283321 | Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis. |
| Q37789173 | Prevalence, gender, ethnic variations, and prognosis of NASH |
| Q39679120 | Prevalences of diabetic retinopathy and nephropathy are lower in Korean type 2 diabetic patients with non-alcoholic fatty liver disease |
| Q63348337 | Procollagen-III peptide identifies adipose tissue-associated inflammation in type 2 diabetes with or without nonalcoholic liver disease |
| Q36050336 | Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes |
| Q34205386 | Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes |
| Q38090905 | Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis |
| Q37089093 | Progressive Depletion of Rough Endoplasmic Reticulum in Epithelial Cells of the Small Intestine in Monosodium Glutamate Mice Model of Obesity |
| Q37580758 | Propranolol, a β-adrenoceptor antagonist, worsens liver injury in a model of non-alcoholic steatohepatitis |
| Q46630941 | Prothrombotic factors and nonalcoholic fatty liver disease: an additional link to cardiovascular risk? |
| Q35890406 | Quantification of Hepatorenal Index for Computer-Aided Fatty Liver Classification with Self-Organizing Map and Fuzzy Stretching from Ultrasonography |
| Q33860061 | Quantification of lipid droplets and associated proteins in cellular models of obesity via high-content/high-throughput microscopy and automated image analysis. |
| Q33900501 | Reduced hepatic eNOS phosphorylation is associated with NAFLD and type 2 diabetes progression and is prevented by daily exercise in hyperphagic OLETF rats |
| Q34362642 | Relationship between Kidney Function and Liver Histology in Subjects with Nonalcoholic Steatohepatitis |
| Q43688306 | Relationship of serum gamma-glutamyltransferase to atherogenic dyslipidemia and glycemic control in type 2 diabetes |
| Q38204970 | Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. |
| Q26775340 | Research advances in the relationship between nonalcoholic fatty liver disease and atherosclerosis |
| Q38202220 | Revisiting the metabolic syndrome and paving the way for microRNAs in non-alcoholic fatty liver disease. |
| Q92462642 | Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease |
| Q37794163 | Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease |
| Q37856102 | Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: just a coincidence? |
| Q37596189 | Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease |
| Q64955233 | Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Nonalcoholic Fatty Liver Disease. |
| Q38760082 | Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance |
| Q37793003 | Roles of liver innate immune cells in nonalcoholic fatty liver disease |
| Q37869788 | SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. |
| Q30577903 | Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. |
| Q89054279 | Screening Strategies for Nonalcoholic Steatohepatitis in High-Risk Individuals: Trimming Away the Fat |
| Q37037308 | Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. |
| Q41128622 | Second-hand smoke stimulates lipid accumulation in the liver by modulating AMPK and SREBP-1. |
| Q43960965 | Serum biomarkers in type 2 diabetic patients with non-alcoholic steatohepatitis and advanced fibrosis |
| Q43736606 | Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab |
| Q36699028 | Sex-influenced association of nonalcoholic fatty liver disease with coronary heart disease. |
| Q34830398 | Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis |
| Q34979386 | Template to improve glycemic control without reducing adiposity or dietary fat. |
| Q90296521 | The Interplay Between Nonalcoholic Fatty Liver Disease and Atherosclerotic Heart Disease |
| Q55384244 | The Oxygen Paradox, the French Paradox, and age-related diseases. |
| Q36838110 | The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease |
| Q40665757 | The Risk of Cardiovascular Disease, Diabetes, Liver-Related Outcomes, and Death Over 10 Years in HIV/HCV-Coinfected Patients With and Without Steatosis |
| Q47847024 | The Role of Metabolic Surgery in Non-alcoholic Steatohepatitis Improvement |
| Q51093729 | The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis. |
| Q35525608 | The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). |
| Q39063496 | The auditory system of the goldfish (Carassius auratus): Effects of intense acoustic stimulation |
| Q24654991 | The blind men 'see' the elephant-the many faces of fatty liver disease |
| Q98830776 | The effects of canola oil compared with sesame and sesame-canola oil on glycemic control and liver function enzymes in patients with type 2 diabetes: A 3-way randomized triple-blind cross-over clinical trial |
| Q38141714 | The genetics of NAFLD. |
| Q92482666 | The hepatokine Tsukushi is released in response to NAFLD and impacts cholesterol homeostasis |
| Q88208317 | The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases |
| Q89624002 | The role of the gut microbiome in chronic liver disease: the clinical evidence revised |
| Q37297977 | Trans fat feeding results in higher serum alanine aminotransferase and increased insulin resistance compared with a standard murine high-fat diet |
| Q26751258 | Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions |
| Q35185301 | Type 2 Diabetes Mellitus-Induced Hyperglycemia in Patients with NAFLD and Normal LFTs: Relationship to Lipid Profile, Oxidative Stress and Pro-Inflammatory Cytokines. |
| Q27016644 | Type 2 diabetes: etiology and reversibility |
| Q51367307 | Type 2 diabetic patients with non-alcoholic fatty liver disease exhibit significant haemorheological abnormalities. |
| Q47200047 | Uneven acute non-alcoholic fatty change of the liver after percutaneous transhepatic portal vein embolization in a patient with hilar cholangiocarcinoma - a case report |
| Q33618565 | Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). |
| Q84194021 | What's in a NAme? |
| Q91591307 | [Conjugated linoleic acid improves glucose and lipid metabolism in diabetic mice] |
| Q92366749 | miR‑146a improves hepatic lipid and glucose metabolism by targeting MED1 |
| Q28648219 | γ-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study |
Search more.